LU92126B1 - Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale - Google Patents

Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Info

Publication number: LU92126B1
Authority: LU; Luxembourg
Prior art keywords: neurodegenerative; neuronal; disorder; disease; prevention
Prior art date: 2012-12-31

Application number

LU92126A

Other languages

English (en)

Original Assignee

Cesa Alliance Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-31

Filing date

2012-12-31

Publication date

2014-07-01

2012-12-31 Priority to LU92126A priority Critical patent/LU92126B1/fr

2012-12-31 Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa

2013-12-17 Priority to BR112015015509-0A priority patent/BR112015015509B1/pt

2013-12-17 Priority to EA201591021A priority patent/EA029650B1/ru

2013-12-17 Priority to NZ710131A priority patent/NZ710131A/en

2013-12-17 Priority to SG11201504744WA priority patent/SG11201504744WA/en

2013-12-17 Priority to PCT/EP2013/076936 priority patent/WO2014102090A1/fr

2013-12-17 Priority to KR1020157020805A priority patent/KR102104155B1/ko

2013-12-17 Priority to PE2015001180A priority patent/PE20151424A1/es

2013-12-17 Priority to UAA201507037A priority patent/UA117822C2/uk

2013-12-17 Priority to AU2013369491A priority patent/AU2013369491B2/en

2013-12-17 Priority to CN201380069044.3A priority patent/CN104884052B/zh

2013-12-17 Priority to MA38307A priority patent/MA38307B1/fr

2013-12-17 Priority to JP2015550024A priority patent/JP6699961B2/ja

2013-12-17 Priority to CA2895429A priority patent/CA2895429C/fr

2013-12-17 Priority to EP13808014.8A priority patent/EP2938337A1/fr

2013-12-17 Priority to MX2015008520A priority patent/MX369590B/es

2013-12-17 Priority to MYPI2015702083A priority patent/MY171832A/en

2013-12-17 Priority to US14/758,343 priority patent/US9284250B2/en

2013-12-27 Priority to ARP130105072A priority patent/AR094318A1/es

2013-12-30 Priority to JOP/2013/0390A priority patent/JO3483B1/ar

2013-12-30 Priority to TW102148993A priority patent/TWI590819B/zh

2013-12-30 Priority to UY0001035253A priority patent/UY35253A/es

2014-07-01 Publication of LU92126B1 publication Critical patent/LU92126B1/fr

2014-07-01 Application granted granted Critical

2015-06-16 Priority to TNP2015000275A priority patent/TN2015000275A1/fr

2015-06-18 Priority to PH12015501402A priority patent/PH12015501402A1/en

2015-06-24 Priority to IL239622A priority patent/IL239622B/en

2015-06-30 Priority to CL2015001881A priority patent/CL2015001881A1/es

2015-07-14 Priority to ZA2015/05057A priority patent/ZA201505057B/en

2016-03-04 Priority to HK16102495.8A priority patent/HK1214517A1/zh

2016-03-14 Priority to US15/069,118 priority patent/US9611205B2/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Psychology (AREA)
Optics & Photonics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LU92126A 2012-12-31 2012-12-31 Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale LU92126B1 (fr)

Priority Applications (29)

Application Number	Priority Date	Filing Date	Title
LU92126A LU92126B1 (fr)	2012-12-31	2012-12-31	Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
MX2015008520A MX369590B (es)	2012-12-31	2013-12-17	4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal.
NZ710131A NZ710131A (en)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
SG11201504744WA SG11201504744WA (en)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PCT/EP2013/076936 WO2014102090A1 (fr)	2012-12-31	2013-12-17	4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
KR1020157020805A KR102104155B1 (ko)	2012-12-31	2013-12-17	인지성, 신경퇴행성 또는 뉴런성 질환의 예방 및 치료를 위한 4-히드록시-2-메틸-5-(프로판-2-일리덴)시클로헥스-3-엔카르브알데히드
PE2015001180A PE20151424A1 (es)	2012-12-31	2013-12-17	Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
UAA201507037A UA117822C2 (uk)	2012-12-31	2013-12-17	4-гідрокси-2-метил-5-(пропан-2-іліден)циклогекс-3-енекарбальдегід у профілактиці та лікуванні когнітивних, нейродегенеративних або нейронних захворювань
AU2013369491A AU2013369491B2 (en)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
CN201380069044.3A CN104884052B (zh)	2012-12-31	2013-12-17	4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用于预防及治疗认知、神经退行性或神经元疾病
MA38307A MA38307B1 (fr)	2012-12-31	2013-12-17	4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
JP2015550024A JP6699961B2 (ja)	2012-12-31	2013-12-17	認知の、神経変性の、または神経の疾患の予防および治療のための４−ヒドロキシ−２−メチル−５−（プロパン−２−イリデン）シクロヘキサ−３−エンカルバルデヒド
CA2895429A CA2895429C (fr)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde pour la prevention et le traitement d'une maladie cognitive, neurodegenerative ou neuronale
EP13808014.8A EP2938337A1 (fr)	2012-12-31	2013-12-17	4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
BR112015015509-0A BR112015015509B1 (pt)	2012-12-31	2013-12-17	Composto farmacêutico para a prevenção e tratamento de uma doença ou desordem cognitiva, neuro degenerativa ou doença neuronal
MYPI2015702083A MY171832A (en)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
EA201591021A EA029650B1 (ru)	2012-12-31	2013-12-17	4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
US14/758,343 US9284250B2 (en)	2012-12-31	2013-12-17	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
ARP130105072A AR094318A1 (es)	2012-12-31	2013-12-27	Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal
JOP/2013/0390A JO3483B1 (ar)	2012-12-31	2013-12-30	4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
TW102148993A TWI590819B (zh)	2012-12-31	2013-12-30	認知、神經退化或神經元失調或疾病之預防及治療用醫藥化合物
UY0001035253A UY35253A (es)	2012-12-31	2013-12-30	Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o una enfermedad cogniti vos, neurodegenerativos o neuronales
TNP2015000275A TN2015000275A1 (fr)	2012-12-31	2015-06-16	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PH12015501402A PH12015501402A1 (en)	2012-12-31	2015-06-18	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
IL239622A IL239622B (en)	2012-12-31	2015-06-24	Preparations for the treatment of neurodegenerative diseases
CL2015001881A CL2015001881A1 (es)	2012-12-31	2015-06-30	Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
ZA2015/05057A ZA201505057B (en)	2012-12-31	2015-07-14	4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive ,neurodegenerative or neuronal disease
HK16102495.8A HK1214517A1 (zh)	2012-12-31	2016-03-04	-羥基- -甲基- 丙- -亞基環己- -烯甲醛用於預防及治療認知、神經退行性或神經元疾病
US15/069,118 US9611205B2 (en)	2012-12-31	2016-03-14	Pharmaceutical compound for the prevention and treatment

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
LU92126A LU92126B1 (fr)	2012-12-31	2012-12-31	Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Publications (1)

Publication Number	Publication Date
LU92126B1 true LU92126B1 (fr)	2014-07-01

Family

ID=47470067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92126A LU92126B1 (fr)	2012-12-31	2012-12-31	Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Country Status (28)

Country	Link
US (2)	US9284250B2 (fr)
EP (1)	EP2938337A1 (fr)
JP (1)	JP6699961B2 (fr)
KR (1)	KR102104155B1 (fr)
CN (1)	CN104884052B (fr)
AR (1)	AR094318A1 (fr)
AU (1)	AU2013369491B2 (fr)
BR (1)	BR112015015509B1 (fr)
CA (1)	CA2895429C (fr)
CL (1)	CL2015001881A1 (fr)
EA (1)	EA029650B1 (fr)
HK (1)	HK1214517A1 (fr)
IL (1)	IL239622B (fr)
JO (1)	JO3483B1 (fr)
LU (1)	LU92126B1 (fr)
MA (1)	MA38307B1 (fr)
MX (1)	MX369590B (fr)
MY (1)	MY171832A (fr)
NZ (1)	NZ710131A (fr)
PE (1)	PE20151424A1 (fr)
PH (1)	PH12015501402A1 (fr)
SG (1)	SG11201504744WA (fr)
TN (1)	TN2015000275A1 (fr)
TW (1)	TWI590819B (fr)
UA (1)	UA117822C2 (fr)
UY (1)	UY35253A (fr)
WO (1)	WO2014102090A1 (fr)
ZA (1)	ZA201505057B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2935303T (lt)	2012-12-21	2021-03-25	Janssen Biopharma, Inc.	4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
WO2018129722A1 (fr) *	2017-01-13	2018-07-19	Bened Biomedical Co., Ltd.	Nouvelle bactérie lactique et ses applications
KR102017415B1 (ko) *	2018-02-13	2019-09-02	연세대학교 산학협력단	뇌 신경 손상 완화용 조성물
CN108813453A (zh) *	2018-05-23	2018-11-16	青岛大学	一种防治帕金森病的食用组合物
US20230200437A1 (en)	2019-12-02	2023-06-29	Philip Morris Products S.A.	Shisha device with trough

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001068576A1 (fr) *	2000-03-10	2001-09-20	Applied Genetics Incorporated Dermatics	Composes dermatologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1511520A (zh) *	2002-12-31	2004-07-14	�й�ҽѧ��ѧԺҩ��о��	丁二酸酯衍生物治疗痴呆症的用途
KR20050109990A (ko) *	2003-03-14	2005-11-22	머크 샤프 앤드 돔 리미티드	경증 인지 장애의 치료 및 알츠하이머 질환의 예방 또는지연 방법

2012
- 2012-12-31 LU LU92126A patent/LU92126B1/fr active
2013
- 2013-12-17 CN CN201380069044.3A patent/CN104884052B/zh active Active
- 2013-12-17 EA EA201591021A patent/EA029650B1/ru unknown
- 2013-12-17 BR BR112015015509-0A patent/BR112015015509B1/pt active IP Right Grant
- 2013-12-17 US US14/758,343 patent/US9284250B2/en active Active
- 2013-12-17 PE PE2015001180A patent/PE20151424A1/es unknown
- 2013-12-17 MX MX2015008520A patent/MX369590B/es active IP Right Grant
- 2013-12-17 MY MYPI2015702083A patent/MY171832A/en unknown
- 2013-12-17 EP EP13808014.8A patent/EP2938337A1/fr not_active Ceased
- 2013-12-17 MA MA38307A patent/MA38307B1/fr unknown
- 2013-12-17 WO PCT/EP2013/076936 patent/WO2014102090A1/fr active Application Filing
- 2013-12-17 JP JP2015550024A patent/JP6699961B2/ja active Active
- 2013-12-17 UA UAA201507037A patent/UA117822C2/uk unknown
- 2013-12-17 AU AU2013369491A patent/AU2013369491B2/en active Active
- 2013-12-17 KR KR1020157020805A patent/KR102104155B1/ko active IP Right Grant
- 2013-12-17 SG SG11201504744WA patent/SG11201504744WA/en unknown
- 2013-12-17 CA CA2895429A patent/CA2895429C/fr active Active
- 2013-12-17 NZ NZ710131A patent/NZ710131A/en unknown
- 2013-12-27 AR ARP130105072A patent/AR094318A1/es not_active Application Discontinuation
- 2013-12-30 UY UY0001035253A patent/UY35253A/es not_active Application Discontinuation
- 2013-12-30 TW TW102148993A patent/TWI590819B/zh active
- 2013-12-30 JO JOP/2013/0390A patent/JO3483B1/ar active
2015
- 2015-06-16 TN TNP2015000275A patent/TN2015000275A1/fr unknown
- 2015-06-18 PH PH12015501402A patent/PH12015501402A1/en unknown
- 2015-06-24 IL IL239622A patent/IL239622B/en active IP Right Grant
- 2015-06-30 CL CL2015001881A patent/CL2015001881A1/es unknown
- 2015-07-14 ZA ZA2015/05057A patent/ZA201505057B/en unknown
2016
- 2016-03-04 HK HK16102495.8A patent/HK1214517A1/zh unknown
- 2016-03-14 US US15/069,118 patent/US9611205B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001068576A1 (fr) *	2000-03-10	2001-09-20	Applied Genetics Incorporated Dermatics	Composes dermatologiques

Also Published As

Publication number	Publication date
HK1214517A1 (zh)	2016-07-29
US9284250B2 (en)	2016-03-15
TW201431550A (zh)	2014-08-16
AU2013369491A1 (en)	2015-08-06
IL239622B (en)	2018-12-31
PE20151424A1 (es)	2015-10-15
CL2015001881A1 (es)	2015-11-06
US9611205B2 (en)	2017-04-04
MX2015008520A (es)	2015-09-10
CN104884052B (zh)	2021-06-25
US20160194266A1 (en)	2016-07-07
EA029650B1 (ru)	2018-04-30
PH12015501402B1 (en)	2015-09-07
IL239622A0 (en)	2015-08-31
UA117822C2 (uk)	2018-10-10
BR112015015509A2 (pt)	2017-07-11
MY171832A (en)	2019-11-01
UY35253A (es)	2014-07-31
EA201591021A1 (ru)	2016-01-29
EP2938337A1 (fr)	2015-11-04
MA38307A1 (fr)	2016-12-30
US20150361020A1 (en)	2015-12-17
KR102104155B1 (ko)	2020-04-24
BR112015015509B1 (pt)	2021-11-30
CN104884052A (zh)	2015-09-02
JP6699961B2 (ja)	2020-05-27
PH12015501402A1 (en)	2015-09-07
AU2013369491A2 (en)	2015-08-13
TWI590819B (zh)	2017-07-11
KR20150102117A (ko)	2015-09-04
JO3483B1 (ar)	2020-07-05
AU2013369491B2 (en)	2018-04-26
AR094318A1 (es)	2015-07-29
MA38307B1 (fr)	2017-11-30
JP2016505600A (ja)	2016-02-25
NZ710131A (en)	2019-08-30
MX369590B (es)	2019-11-13
ZA201505057B (en)	2016-07-27
TN2015000275A1 (fr)	2016-10-03
CA2895429C (fr)	2019-04-16
WO2014102090A1 (fr)	2014-07-03
CA2895429A1 (fr)	2014-07-03
SG11201504744WA (en)	2015-07-30

Publication	Publication Date	Title
MA44699A (fr)	2021-05-05	Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
EP2817673A4 (fr)	2016-03-02	Ralentissement de la progression de la myopie et/ou traitement ou prévention de la myopie ou d'une maladie ou d'un état associé à la myopie
EP2683382A4 (fr)	2014-10-22	Régimes posologiques pour le traitement de la maladie de fabry
EP2818482A4 (fr)	2015-10-07	Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2818481A4 (fr)	2015-10-07	Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2844279A4 (fr)	2015-12-16	Schéma posologique pour le traitement de la maladie de pompe
EP2889032A4 (fr)	2016-03-09	Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole
EP2800578A4 (fr)	2015-07-15	Signalisation de slit-robo pour le diagnostic et le traitement d'une maladie rénale
LU92126B1 (fr)	2014-07-01	Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
EP3344325A4 (fr)	2019-05-15	Administration locale de médicaments pour le traitement de l'asthme
EP3395364A4 (fr)	2019-09-04	Médicament contenant un inhibiteur de caspase pour le traitement ou la prévention de trouble provoqué par tgf- , et son application
EP2959903A4 (fr)	2016-08-03	Médicament pour le traitement de maladie des yeux
EP2786758A4 (fr)	2015-04-29	Composition pharmaceutique pour la prévention ou le traitement de troubles des fonctions cognitives comprenant de la spinosyne
EP2999444A4 (fr)	2016-10-12	Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
EP3324944A4 (fr)	2019-04-03	Systèmes d'administration de médicaments intravitréens pour le traitement d'états oculaires
MA41689A (fr)	2017-08-22	Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
EP2962693A4 (fr)	2016-08-03	Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer
EP2900259A4 (fr)	2016-07-13	Schéma posologique de glycosidase pour le traitement d'une maladie infectieuse
EP3329929A4 (fr)	2019-04-03	Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire
EP2676665A4 (fr)	2014-09-24	Utilisation de la mangostine- dans la préparation de médicaments destinés à traiter la maladie d'alzheimer
EP3302443A4 (fr)	2019-02-13	Microcapsules mécano-sensibles pour l'administration de médicaments
EP3398614A4 (fr)	2019-12-25	Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
MA47595A (fr)	2020-01-01	Méthodes de traitement d'affections neurodégénératives
EP2946777A4 (fr)	2016-09-21	Médicament pour le traitement d'une maladie neuropathique
EP3395350A4 (fr)	2019-09-18	Médicament pour le traitement des infarctus cérébraux